Skip to main content

Press Releases and Ad-hoc Announcements

13 July 2022
AH: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
PDF
12 July 2022
PR: Heidelberg Pharma Reports on First Half-Year 2022
PDF
28 June 2022
PR: Heidelberg Pharma Reports Outcome of the Annual General Meeting 2022
PDF
09 May 2022
AH: Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure
PDF
28 April 2022
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022
PDF
07 April 2022
PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC® Technology Platform at the AACR Annual Meeting 2022
PDF
24 March 2022
PR: Heidelberg Pharma Announces Financial Figures for Fiscal Year 2021 and Provides Business Update
PDF
10 March 2022
PR: Heidelberg Pharma Receives Milestone Payment from Partner Magenta for Dosing the First Patient with MGTA-117
PDF
28 February 2022
PR: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
PDF
27 February 2022
AH: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
PDF
17 February 2022
AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
PDF
15 February 2022
PR: Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
PDF
28 October 2021
PR: Heidelberg Pharma Participates at Various Conferences
PDF
07 October 2021
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
PDF
01 October 2021
PR: Heidelberg Pharma AG Announces Adjustment of Guidance
PDF
09 September 2021
PR: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
PDF
07 September 2021
PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US
PDF
19 July 2021
PR: Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
PDF
08 July 2021
PR: Heidelberg Pharma Reports on First Half-Year 2021
PDF
17 June 2021
PR: Heidelberg Pharma Announces Participation at Various Conferences
PDF
15 June 2021
Heidelberg Pharma AG Raises EUR 20 Million From Private Placement
PDF
15 June 2021
AH: Heidelberg Pharma AG to Raise Capital in a Private Placement
PDF
18 May 2021
PM: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions
PDF
29 April 2021
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021
PDF
31 March 2021
PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
PDF
25 March 2021
PR: Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
PDF
19 March 2021
AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
PDF
01 March 2021
PR: Heidelberg Pharma Expands Management Team
PDF
11 February 2021
PR: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
PDF
04 February 2021
AH: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
PDF